This adds to the already promising prospects of KCC2 activators for other neurological disorders such as for the treatment of seizures (Moore et al., 2017, 2018), a common co-morbidity of autism-spectrum disorders. This evidence concerns the gene SLC12A5 and nervous system disorder.